News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN)'s Thyroid Cancer Drug Caprelsa Gets EU Approval


2/21/2012 7:44:11 AM

British drug maker AstraZeneca Plc (AZN: News ,AZN.L: News ) on Tuesday said the European Commission has granted marketing authorisation for Caprelsa (vandetanib). This is for the treatment of aggressive and symptomatic medullary thyroid cancer or MTC in patients with unresectable locally advanced or metastatic disease. The company noted that the drug, a prescription oral kinase inhibitor treatment, is the first approved treatment for advanced MTC in Europe. The marketing authorisation of CAPRELSA is based on data from the Phase III CAPRELSA clinical trial program, including the ZETA study.

Read at RTT News
Read at Market Watch
Read at Fox News
Read at Reuters


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES